BioVie, Inc. Common Stock (BIVI) News

Latest headlines that mention BIVI, newest first · each headline opens the original publisher

BIVI quote

Last price: $1.33
Day change: +7.26%
Next earnings: 2026-11-09

Quote & chart Expected move Insider trading IV rank history

BIVI headlines

latest coverage

Seeking Alpha News 1mo ago

BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript

General T2BIVI

Seeking Alpha News 1mo ago

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid - Slideshow

General T2BIVI

Seeking Alpha News 1mo ago

BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript

General T2BIVI

Investing.com 1mo ago

Biovie director Amy Chappell acquires $1,570 in BIVI common stock

M&A T3BIVI

Investing.com 1mo ago

Biovie CMO Joseph Palumbo buys $10,460 in common stock

General T3BIVI

Investing.com 1mo ago

Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock

General T3BIVI

Investing.com 1mo ago

BioVie Inc. CEO Cuong V Do buys $31,636 in company stock

General T3BIVI

Seeking Alpha News 2mo ago

BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript

General T2BIVI

Seeking Alpha News 4mo ago

BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript

General T2BIVI

Investing.com 5mo ago

BioVie completes enrollment in Long COVID treatment trial

General T3BIVI

Investing.com 5mo ago

Form 10Q Biovie Inc For: 11 May

General T3BIVI

Seeking Alpha News 5mo ago

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

General T2BIVI

BIVI news alerts

Get an alert by email or push when a new headline mentions BIVI.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.